Effects of amitriptyline and imipranimine on brain amine neurotransmitter metabolites in cerebrospinal fluid

Charles L. Bowden, Stephen H. Koslow, Israel Hanin, James W. Maas, John M. Davis, Eli Robins

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The effects of amitriptyline (AMI) or imipramine (IMI) on levels of 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA) (the major brain metabolites of the neurotransmitters norepinephrine [NE], serotonin [5-HT], and dopamine [DA]) in cerebrospinal fluid were determined in 66 subjects with unipolar and bipolar depression. There were significant reductions in MHPG and 5-HIAA levels for the depressed group taken as a whole, but levels of HVA did not change significantly. The changes were similar when subjects were grouped as treated with AMI and IMI and with unipolar and bipolar depression. Reductions in MHPG and 5-HLAA levels were greater in women than in men. In all subjects with depression and in those treated with AMI and IMI, amine metabolite changes did not differ significantly between those who had a positive clinical response to drug therapy and those who did not. Responders with bipolar depression had smaller reductions in MHPG levels than did responders with unipolar depression. The similar effects of AMI and IMI on MHPG and 5-HIAA differ from the dissimilar effects of the two drugs on NE and 5-HT amine uptake systems reported in animal and in in vitro studies. Results provide conclusive evidence of the effects of AMI and IMI on noradrenergic and serotonergic (but not dopaminergic) systems in patients with depression.

Original languageEnglish (US)
Pages (from-to)316-324
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume37
Issue number3
StatePublished - Mar 1985

Fingerprint

Amitriptyline
Imipramine
Amines
Neurotransmitter Agents
Cerebrospinal Fluid
Hydroxyindoleacetic Acid
Depressive Disorder
Bipolar Disorder
Brain
Serotonin
Homovanillic Acid
Norepinephrine
Depression
Dopamine
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Bowden, C. L., Koslow, S. H., Hanin, I., Maas, J. W., Davis, J. M., & Robins, E. (1985). Effects of amitriptyline and imipranimine on brain amine neurotransmitter metabolites in cerebrospinal fluid. Clinical Pharmacology and Therapeutics, 37(3), 316-324.

Effects of amitriptyline and imipranimine on brain amine neurotransmitter metabolites in cerebrospinal fluid. / Bowden, Charles L.; Koslow, Stephen H.; Hanin, Israel; Maas, James W.; Davis, John M.; Robins, Eli.

In: Clinical Pharmacology and Therapeutics, Vol. 37, No. 3, 03.1985, p. 316-324.

Research output: Contribution to journalArticle

Bowden, CL, Koslow, SH, Hanin, I, Maas, JW, Davis, JM & Robins, E 1985, 'Effects of amitriptyline and imipranimine on brain amine neurotransmitter metabolites in cerebrospinal fluid', Clinical Pharmacology and Therapeutics, vol. 37, no. 3, pp. 316-324.
Bowden, Charles L. ; Koslow, Stephen H. ; Hanin, Israel ; Maas, James W. ; Davis, John M. ; Robins, Eli. / Effects of amitriptyline and imipranimine on brain amine neurotransmitter metabolites in cerebrospinal fluid. In: Clinical Pharmacology and Therapeutics. 1985 ; Vol. 37, No. 3. pp. 316-324.
@article{8a7f6ba667f443db83c12f6b2c965799,
title = "Effects of amitriptyline and imipranimine on brain amine neurotransmitter metabolites in cerebrospinal fluid",
abstract = "The effects of amitriptyline (AMI) or imipramine (IMI) on levels of 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA) (the major brain metabolites of the neurotransmitters norepinephrine [NE], serotonin [5-HT], and dopamine [DA]) in cerebrospinal fluid were determined in 66 subjects with unipolar and bipolar depression. There were significant reductions in MHPG and 5-HIAA levels for the depressed group taken as a whole, but levels of HVA did not change significantly. The changes were similar when subjects were grouped as treated with AMI and IMI and with unipolar and bipolar depression. Reductions in MHPG and 5-HLAA levels were greater in women than in men. In all subjects with depression and in those treated with AMI and IMI, amine metabolite changes did not differ significantly between those who had a positive clinical response to drug therapy and those who did not. Responders with bipolar depression had smaller reductions in MHPG levels than did responders with unipolar depression. The similar effects of AMI and IMI on MHPG and 5-HIAA differ from the dissimilar effects of the two drugs on NE and 5-HT amine uptake systems reported in animal and in in vitro studies. Results provide conclusive evidence of the effects of AMI and IMI on noradrenergic and serotonergic (but not dopaminergic) systems in patients with depression.",
author = "Bowden, {Charles L.} and Koslow, {Stephen H.} and Israel Hanin and Maas, {James W.} and Davis, {John M.} and Eli Robins",
year = "1985",
month = "3",
language = "English (US)",
volume = "37",
pages = "316--324",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Effects of amitriptyline and imipranimine on brain amine neurotransmitter metabolites in cerebrospinal fluid

AU - Bowden, Charles L.

AU - Koslow, Stephen H.

AU - Hanin, Israel

AU - Maas, James W.

AU - Davis, John M.

AU - Robins, Eli

PY - 1985/3

Y1 - 1985/3

N2 - The effects of amitriptyline (AMI) or imipramine (IMI) on levels of 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA) (the major brain metabolites of the neurotransmitters norepinephrine [NE], serotonin [5-HT], and dopamine [DA]) in cerebrospinal fluid were determined in 66 subjects with unipolar and bipolar depression. There were significant reductions in MHPG and 5-HIAA levels for the depressed group taken as a whole, but levels of HVA did not change significantly. The changes were similar when subjects were grouped as treated with AMI and IMI and with unipolar and bipolar depression. Reductions in MHPG and 5-HLAA levels were greater in women than in men. In all subjects with depression and in those treated with AMI and IMI, amine metabolite changes did not differ significantly between those who had a positive clinical response to drug therapy and those who did not. Responders with bipolar depression had smaller reductions in MHPG levels than did responders with unipolar depression. The similar effects of AMI and IMI on MHPG and 5-HIAA differ from the dissimilar effects of the two drugs on NE and 5-HT amine uptake systems reported in animal and in in vitro studies. Results provide conclusive evidence of the effects of AMI and IMI on noradrenergic and serotonergic (but not dopaminergic) systems in patients with depression.

AB - The effects of amitriptyline (AMI) or imipramine (IMI) on levels of 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA) (the major brain metabolites of the neurotransmitters norepinephrine [NE], serotonin [5-HT], and dopamine [DA]) in cerebrospinal fluid were determined in 66 subjects with unipolar and bipolar depression. There were significant reductions in MHPG and 5-HIAA levels for the depressed group taken as a whole, but levels of HVA did not change significantly. The changes were similar when subjects were grouped as treated with AMI and IMI and with unipolar and bipolar depression. Reductions in MHPG and 5-HLAA levels were greater in women than in men. In all subjects with depression and in those treated with AMI and IMI, amine metabolite changes did not differ significantly between those who had a positive clinical response to drug therapy and those who did not. Responders with bipolar depression had smaller reductions in MHPG levels than did responders with unipolar depression. The similar effects of AMI and IMI on MHPG and 5-HIAA differ from the dissimilar effects of the two drugs on NE and 5-HT amine uptake systems reported in animal and in in vitro studies. Results provide conclusive evidence of the effects of AMI and IMI on noradrenergic and serotonergic (but not dopaminergic) systems in patients with depression.

UR - http://www.scopus.com/inward/record.url?scp=0021995125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021995125&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 316

EP - 324

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -